The co-administration of allosteric drug ABL001 and classical TKIs targeting BCR-ABL1, (including imatinib, NIL, and dasatinib) for the therapy of CML achieved persistent and complete regression of the malignancy and addressed historically notorious resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.